![GettyImages-1227710766-600x400](https://medphanut.com/wp-content/uploads/2024/06/GettyImages-1227710766-600x400-600x381.jpg)
Geron Corporation’s Rytelo is now FDA approved for treating anemia caused by myelodysplastic syndromes. The new drug will compete against Reblozyl, a blockbuster Bristol Myers Squibb medicine.
The post Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer appeared first on MedCity News.